I24 News : Israeli Drugmaker Oramed Successfully Tests Insulin Pill
http://www.dailymotion.com/video/x4jqi3z
Biopharma Dive: Oramed’s oral insulin shines in mid-stage trials
Creating a safe, effective, tolerable oral insulin has become the holy grail of diabetes drug development, and Israel-based Oramed is one of the frontrunners in this race... http://www.biopharmadive.com/news/orameds-oral-insulin-shines-in-mid-stage-trials/419657/
Market Exclusive: Weekly Biotech Report Part II, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)
https://marketexclusive.com/weekly-biotech-report-part-ii-oramed-pharmaceuticals-inc-nasdaqormp/2016/05/
Reuters: Oramed Says Oral Insulin Succeeds in Midstage Type 2 Diabetes Trial
http://www.reuters.com/article/us-oramed-insulin-idUSKCN0Y91F2
Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
JERUSALEM, April 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place [...]
Oramed Completes Phase IIb Oral Insulin Study
Top-Line Data to be Released This Quarter JERUSALEM, April 5, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that all follow-up visits in the Company's Phase IIb study of its oral [...]
Oramed Patent Granted in India for Oral Administration of Proteins
JERUSALEM, March 29, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins" has been granted by the Indian Patent Office. About Oramed [...]
Be Forum: Dancing With Dragons, How a Small Israeli Company Struck a Historic Deal with a Chinese Giant
Josh Hexter, Oramed's COO, spoke with Be Forum and about the company's recent China deal. www.beforum.org/the-bulletin/dancing-with-dragons
BioTuesdays: Oramed sees value creating events through 2016
Josh Hexter, Oramed's COO, spoke with BioTuesdays.com about Oramed's progress and future advances. "Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and [...]
Seeking Alpha: $50 Million Plus Royalties Deal Indicates Bright Future For Oramed’s Oral Insulin
seekingalpha.com/article/3723676-50-million-plus-royalties-deal-indicates-bright-future-for-orameds-oral-insulin?app=1&auth_param=k8111%3A1b5r8j9%3A005181aa590ef2f22df1979bdbb995c2&uprof=78